#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarter

Elizabeth Cairns / endpoints - Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have never had a heart attack or stroke. Repatha is already ...

AI Summary: At AHA25 in New Orleans, researchers and clinicians showcased pivotal findings – including Amgen’s cholesterol‐lowering drug cutting first‐time cardiovascular events by 25% – while experts like Avirup Guha highlighted innovative cardio‐oncology sessions. The event spotlighted the evolving intersection between heart health and cancer care.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Statins Rarely Cause Listed Side Effects, Review Confirms / 3 months

FDA Greenlights Subcutaneous Daratumumab for Smoldering Multiple Myeloma / 6 months

Intellia CRISPR Trial Fatality Raises Safety Concerns / 6 months

Apixaban linked to lower bleeding than rivaroxaban in head‑to‑head study / 2 months

Hormone therapy adds no clear benefit to salvage radiotherapy / 2 months

Life-extending prostate cancer drug to be offered to thousands in England / 4 months

DEA extends telehealth controlled substance flexibilities for 2026 / 4 months